Enhanced sensitivity of laforin- and malin-deficient mice to the convulsant agent pentylenetetrazole by Ana M. GarcÃ­a-Cabrero et al.
ORIGINAL RESEARCH ARTICLE
published: 12 September 2014
doi: 10.3389/fnins.2014.00291
Enhanced sensitivity of laforin- and malin-deficient mice to
the convulsant agent pentylenetetrazole
Ana M. García-Cabrero1,2, Gentzane Sánchez-Elexpuru1,2, José M. Serratosa1,2* and
Marina P. Sánchez1,2*
1 Laboratory of Neurology, IIS-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain
2 Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain
Edited by:
Jesus Avila, Centro de Biología
Molecular Severo Ochoa Consejo
Superior de Investigaciones
Científicas-Universidad Autónoma
de Madrid, Spain
Reviewed by:
Matthew S. Gentry, University of
Kentucky, USA
Tobias Engel, Royal College of
Surgeons, Ireland
*Correspondence:
José M. Serratosa and Marina P.
Sánchez, Laboratory of Neurology,
IIS-Fundación Jiménez Díaz,
Universidad Autónoma de Madrid,
Av. Reyes Católicos 2,
28040 Madrid, Spain
e-mail: jmserratosa@fjd.es;
msanchezg@fjd.es
Lafora disease is a rare form of inherited progressive myoclonus epilepsy caused by
mutations in the EPM2A gene encoding laforin, or in the EPM2B gene, which encodes
malin. It is characterized by the presence of polyglucosan inclusion bodies (Lafora bodies)
in brain and other tissues. Genetically engineered mice lacking expression of either
the laforin (Epm2a−/−) or malin (Epm2b−/−) genes display a number of neurological
and behavioral abnormalities that resemble those found in patients suffering from
Lafora disease; of these, both Epm2a−/− and Epm2b−/− mice have shown altered
motor activity, impaired motor coordination, episodic memory deficits, and different
degrees of spontaneous epileptic activity. In this study, we analyze the sensitivity of
Epm2a−/− and Epm2b−/− mice to the convulsant drug pentylenetetrazol (PTZ), an
antagonist of the γ-aminobutyric acid type A (GABAA) receptor, commonly used to
induce epileptic tonic-clonic seizures in laboratory animals. PTZ-induced epileptic activity,
including myoclonic jerks and tonic-clonic seizures, was analyzed in 2 age groups of mice
comprising representative samples of young adult and aged mice, after administration
of PTZ at sub-convulsive and convulsive doses. Epm2a−/− and Epm2b−/− mice showed
a lower convulsive threshold after PTZ injections at sub-convulsive doses. A lower
convulsive threshold and shorter latencies to develop epileptic seizures were observed
after PTZ injections at convulsive doses. Different patterns of generalized seizures and of
discharges were observed in Epm2a−/− and Epm2b−/− mice. Epm2a−/− and Epm2b−/−
mice present an increased sensitivity to the convulsant agent PTZ that may reflect different
degrees of increased GABAA receptor-mediated hyperexcitability.
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INTRODUCTION
Lafora disease (LD) is a rare form of inherited progressive
myoclonus epilepsy (OMIM#254780; ORPHA501). Recessive
mutations in either the EPM2A gene encoding a dual-specificity
phosphatase known as laforin (OMIM 607566) (Minassian et al.,
1998; Serratosa et al., 1999) or in the EPM2B/NHLRC1 gene
encoding malin (OMIM 608072), an E3 ubiquitin ligase (Chan
et al., 2003; Gentry et al., 2005; Gomez-Abad et al., 2005; Singh
et al., 2005, 2006) are responsible for the disease, although the
existence of a third, minor locus has also been postulated (Chan
et al., 2004).
Patients with LD develop progressive myoclonus epilepsy
that usually starts in adolescence and includes absence, visual,
myoclonic, and tonic-clonic seizures accompanied by rapid neu-
rologic degeneration, including ataxia, dementia, dysarthria,
amaurosis, respiratory failure, and a final vegetative state and
death, usually within 10 years of onset (Lafora, 1911; Van Heycop
Ten Ham, 1974; Berkovic et al., 1986, 1991; Roger et al., 1992;
Acharya et al., 1995). The principal pathologic feature of LD is
the presence of periodic acid-Schiff (PAS)-positive intracellular
inclusions of polyglucosans (Lafora bodies) located mainly in the
brain, the skeletal muscle, the heart, and the liver (Lafora, 1911;
Lafora and Glueck, 1911; Harriman et al., 1955; Yokoi et al.,
1968; Sakai et al., 1970; Carpenter and Karpati, 1981; Berkovic
et al., 1986). Currently, no preventive or curative therapies exist
for LD.
Different mouse models have been generated by disrupt-
ing either the Epm2a (Ganesh et al., 2002) or the Epm2b gene
(Depaoli-Roach et al., 2010; Turnbull et al., 2010; Valles-Ortega
et al., 2011; Criado et al., 2012). Of these, the Epm2a−/− mouse
line generated by Ganesh et al. (2002) displays many of the neu-
rological and behavioral abnormalities found in LD patients,
including neuronal degeneration and the development of Lafora
bodies in different organs including heart, liver, muscle, and a
variety of brain regions such as hippocampus, cerebral cortex,
thalamus, cerebellum, and brainstem (Ganesh et al., 2002). In
addition, the Epm2b−/− mouse line previously generated by our
group (Criado et al., 2012) also shows substantial neurological
abnormalities that correlated with the detection of Lafora bodies
in the same brain regions as those of the Epm2a−/− mouse line
(Criado et al., 2012). Of those neurological abnormalities, both
laforin-deficient and malin-deficient mouse lines showed altered
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motor activity, impaired motor coordination, episodic memory
deficits, and different degrees of spontaneous epileptic activity,
such as spontaneous single spikes, polyspikes and spike-wave
and polyspike-wave complexes correlating with myoclonic jerks
(Ganesh et al., 2002; Criado et al., 2012; Garcia-Cabrero et al.,
2012). Epm2a−/− and Epm2b−/− mice had spontaneous tonic-
clonic seizures, although the Epm2b−/− mice did not display EEG
correlates (Garcia-Cabrero et al., 2012).
Here we analyze the responses of both Epm2a−/− and
Epm2b−/− mice to the administration of the epileptogenic agent
pentylenetetrazole (PTZ). PTZ is widely used for the study
of epileptiform activity in laboratory animals (Vernadakis and
Woodbury, 1969; Reinhard and Reinhard, 1977; Swinyard et al.,
1989), and is also used routinely to test antiepileptic drugs
(Swinyard et al., 1989). PTZ is an antagonist of the type A recep-
tor of γ-aminobutyric acid (GABAA) (Stone, 1970). As with other
GABAA antagonists, administration of low doses of PTZ can
result in absence seizures in animal models (Snead et al., 2000),
whereas higher doses result in generalized tonic-clonic seizures
(Woodbury et al., 1980; Panagopoulos et al., 1998; Coimbra
et al., 2001a,b; Erakovic et al., 2001; Eloqayli et al., 2003). In
this study, we used PTZ at both sub-convulsive and convulsive
doses to analyze seizure thresholds in an attempt to elucidate
the molecular mechanisms underlying altered neuronal excitabil-
ity in Epm2a−/− and Epm2b−/− mice and to further evaluate
novel therapeutic strategies to treat epileptic symptoms. PTZ
induces seizure development shortly after injection (Pitkanen
et al., 2006), with reversible effects and low toxicity at convul-
sive doses (Velisek, 2006), whereas other seizure inducing agents
such as methionine sulfoximine or kainate (Dudek et al., 2006;
Eid et al., 2008; Cloix and Hevor, 2009), induce development
of seizures with long pre-convulsive periods of several hours,
and others produce therapy-resistant seizures, e.g., strichnine
(Löscher, 1997). This makes PTZ the most appropriate agent for
seizure monitoring in our models.
MATERIALS AND METHODS
EXPERIMENTAL ANIMALS
Generation of Epm2a−/− mutant mice (Ganesh et al., 2002)
was performed by targeted deletion of the fourth exon of the
Epm2a gene (Minassian et al., 1998; Serratosa et al., 1999), which
encodes the dual-specificity phosphatase domain that is criti-
cal for the function of laforin. Constitutive Epm2b−/− mutant
mice were generated by targeting deletion of the unique exon
encoding malin, as previously described (Criado et al., 2012).
The genetic background of null-mouse lines used in the study
was a mix of 129Sv:C57BL/6J (25%:75%). The mice were kept at
the IIS-Fundación Jimenez Jiménez Díaz animal facility and were
maintained on a 12:12-h light/dark cycle under constant temper-
ature (23◦C) with free access to regular food and water ad libitum.
Two groups of homozygous animals aged 4–8 and 9–23 months
(representative samples of young adult and aged mice) were ana-
lyzed for each experiment. The experiments were conducted in
accordance with the Declaration of Helsinki principles and the
guidelines of the Institutional Animal Care and Use Committee,
and were approved by the IIS-Fundación Jiménez Díaz ethical
review board.
HISTOLOGY AND IMMUNOSHISTOCHEMISTRY
The animals were anesthetized with a mixture of medetomi-
dine (Domitor, Pfizer, Espoo, Finland), ketamine (Ketolar, Pfizer,
Espoo, Finland), and sterile water (1:1.5:1.5) and transcardially
perfused with 4% phosphate-buffered paraformaldehyde. The
animals’ brains were removed, postfixed overnight at 4◦C, dehy-
drated in graded ethanol solutions, and embedded in paraffin.
They were then sectioned in serial arrays of 7-μm-thick sec-
tions, deparaffinized at 60◦C, and stored at room temperature
until use. For PAS staining, coronal sections were processed as
previously described (Mitsuno et al., 1999), and counterstained
with hematoxylin solution. For immunohistochemistry, contigu-
ous PAS-stained sections were rehydrated and incubated in 1.5%
(vol/vol) H2O2 in methanol for 20min at room temperature
to inactivate endogenous peroxidase. Sections were then placed
in blocking buffer for 60min at room temperature and incu-
bated for 3 days at 4◦C with anti-ubiquitin antibody (Dako,
Glostrup, Denmark). Subsequently, the sections were treated with
anti-rabbit biotinylated secondary antibody and stained using
the Vectastain ABC kit (Vector Laboratories, Burlingame, CA,
USA). Immunoreactivity was developed with diaminobenzidine
(Dako, Glostrup, Denmark), and sections were counterstained
with hematoxylin solution, dehydrated, and covered with DePeX
(SERVA Electrophoresis GmbH, Heidelberg, Germany).
PTZ TREATMENT
PTZ (Sigma Chemicals, St. Louis, MO, USA) was dissolved in
sterile water and injected intraperitoneally at different doses as a
single injection. The doses administered were those known to be
sub-convulsive (30mg/kg) (Erakovic et al., 2001) and convulsive
(50mg/kg) (Erakovic et al., 2001; Eloqayli et al., 2003) for control
mice. As described previously, a dose of 50mg/kg induces seizures
in 50% of control animals (Shitak et al., 2006). After drug admin-
istration, PTZ-induced myoclonic jerks and seizure monitoring
was performed in 16–36 mice per group using visual blinded
observation over a period of 45min. The percentages of mice
displaying myoclonic jerks and generalized tonic-clonic seizures
were recorded in 3 groups of control, Epm2a−/−, and Epm2b−/−
mice at 4–8 and 9–23 months of age. Following injection of
PTZ, mice displayed periods of immobility and overt evidence of
convulsive activity which included hyperactivity, twitching, and
hyperextension of the limbs that at times progresses to general-
ized tonic-clonic seizures. We recorded the percentages of PTZ
injected mice that present both muscular jerks, which usually
started within a few minutes of PTZ injection, and generalized
tonic-clonic seizures. To assess for the presence of EEG corre-
lates, twelve mice chosen at random as representative samples of
these 3 groups at 4–8 and 9–23 months underwent surgery and
analysis by video-EEG after PTZ injection at convulsive doses.
EEG recordings of operated mice revealed the existence of iso-
lated spikes and spike-waves that correlate with muscular jerks.
Generalized tonic-clonic seizures with low-frequency (3–6Hz)
spike-wave correlates were also observed in EEGs. Latency—or
time between injection and onset of seizures—and seizure length
were also analyzed for those mice treated with 50mg/kg PTZ.
In addition to measuring epileptic activity, PTZ-induced lethality
was also analyzed for each drug dose.
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VIDEO-ELECTROENCEPHALOGRAPHIC (EEG) RECORDING
Procedures for implantation of intracranial electrodes and
video-EEG recording have been previously described (Criado
et al., 2012; Garcia-Cabrero et al., 2012). Briefly, custom-made
stainless-steel screw electrodes were fixed to the skulls of anes-
thetized animals under a mixture of medetomidine, ketamine
and sterile water (1:1.5:1.5). Two monopolar epidural electrodes
were implanted symmetrically over the frontal cortex in front
of bregma, whereas 2 ground and reference electrodes were
positioned posterior to lambda. After a 4-day recovery period,
synchronized video-EEG activity was recorded using computer-
based systems (Easy EEG 2.1, Cadwell, CA, USA and Natus
Neurowork EEG, Natus Medical Inc., San Carlos, CA, USA) while
the mice moved freely.
STATISTICAL ANALYSIS
Values are given as means ± standard error of means (SEM)
or percentages. Differences between groups were analyzed by
two-tailed Student’s t-test or Chi-square (Graph-Pad Prism 2.0).
Statistical significance was considered to be reached at ∗p < 0.05;
∗∗p < 0.01; ∗∗∗p < 0.001.
RESULTS
PRESENCE OF LAFORA BODIES IN Epm2a−/− AND Epm2b−/− MICE
As in previous descriptions, Lafora inclusions were abundant
in several brain regions of the Epm2a−/− and Epm2b−/− mice,
including cerebral cortex, hippocampus, basal ganglia, thalamus,
cerebellum, and brainstem (Criado et al., 2012; Garcia-Cabrero
et al., 2012). Representative examples of neurons of Layers IV-V of
the cortex exhibiting PAS-positive Lafora aggregates in cell bod-
ies of Epm2a−/− and Epm2b−/− at 17 months of age are shown
in Figures 1A,B, respectively. Intracellular inclusions immunos-
tained for ubiquitin were also found in the same regions as
PAS-positive inclusions (Figures 1C,D).
FIGURE 1 | Lafora bodies in Epm2a−/− and Epm2b−/− mice brains.
Citoplasmic polyglucosan inclusions (arrows) positive for periodic acid-Shiff
staining (PAS) (A,B) in layer V of the cerebral cortex, and immunostained for
ubiquitin (C,D) in Layer IV (C) and IV-V (D) of cerebral cortex of Epm2a−/−
(A,C) and Epm2b−/− (B,D) mice at 17 months of age. Scale bar = 20μm.
ANALYSIS OF PTZ-INDUCED MYOCLONUS, GENERALIZED
TONIC-CLONIC SEIZURES, AND LETHALITY IN MICE LACKING LAFORIN
OR MALIN
Following injection of PTZ, control mice displayed periods
of immobility and overt evidence of convulsive activity which
included hyperactivity, twitching, and hyperextension of the
limbs, later progressing to generalized tonic-clonic seizures. We
established scores for the presence of both myoclonic jerks which
usually started within a few minutes of PTZ injection, and tonic-
clonic seizures. EEG recordings of operated mice revealed the
existence of isolated spikes and spike-wave correlates. At subcon-
vulsive doses, the percentage of mutant mice showing myoclonic
jerks was higher than that of control mice (Figure 2A). Thus, at
this dose, 45% of Epm2a−/− and 50% of Epm2b−/− mice at 4–
8 months displayed myoclonic jerks, compared to only 7% of
age-matched control mice. In the 9-to-23-month mice group,
myoclonic jerks were present in 67% of Epm2a−/− and 75% of
Epm2b−/−, compared to only 22% of control mice. When the
induction of myoclonic jerks was analyzed at a higher dose of
PTZ (50mg/kg), no major differences were observed between
controls and Epm2a−/− or Epm2b−/− mice (Figure 2B). These
results indicate that a sub-convulsive dose of the epileptogenic
drug PTZ induces the appearance of myoclonic jerks more eas-
ily in both young and old mice lacking the expression of either
laforin or malin proteins, as compared to age-matched con-
trols. Although both Epm2a−/− and Epm2b−/− mice trend to
present more myoclonic jerks with age, no statistical differences
were found between young and older mice. After administra-
tion of subconvulsive doses of PTZ in control, Epm2a−/−, or
Epm2b−/− mice at 4–8 months of age, no generalized tonic-
clonic seizures were observed (Figure 2C). However, in the
oldest group, a small proportion of mice displayed seizures,
though no significant differences were recorded between con-
trol and mutant mice (6% control, 13% Epm2a−/−, and 3%
Epm2b−/−) (Figure 2C). As expected, a convulsive PTZ dose at
4–8 months of age induced tonic-clonic seizures in 50% of con-
trol mice (Figure 2D). Interestingly, this percentage was notably
increased for both Epm2a−/− (80%) and Epm2b−/− (78%) mice
(Figure 2D). Similar results were obtained for Epm2a−/− (78%)
mice at 9–23 months, whereas no major differences between con-
trol and Epm2b−/− mice were noticed at this age (Figure 2D).
Lethality thresholds were not affected in either Epm2a−/− or
Epm2b−/− mice at any PTZ dose as compared to age-matched
controls (data not shown).
PTZ-INDUCED SEIZURE LATENCY AND LENGTH
Latency, or the time elapsed between injection of a convulsive
dose of PTZ (50mg/kg) and tonic-clonic seizure appearance, was
recorded for controls, Epm2a−/−, and Epm2b−/− mice. Mutant
mice in both age ranges showed statistically significant reductions
in seizure latency when compared to age-matched control mice
(Figure 3A). Additionally, the length of PTZ-induced seizures
in the Epm2b−/− model at 4–8 months of age was significantly
increased (Figure 3B). The length of PTZ-induced seizures in
the Epm2a−/− mice at 9–23 months of age was also increased,
although no significant differences were observed between old
Epm2a−/− or Epm2b−/− mice and age-matched controls.
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FIGURE 2 | Increased sensitivity of Epm2a−/− and Epm2b−/−
models to the chemoconvulsant agent PTZ. Two different age
groups (4–8 and 9–23 months) of control, Epm2a−/−, and Epm2b−/−
mice were injected intraperitoneally with 30 (A,C) and 50mg/kg of
PTZ (B,D) and the percentages of mice showing PTZ-induced
myoclonus (A,B), and generalized seizures (C,D) were recorded
∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001, Chi-square (n = 16–36 mice per
group at each PTZ dose).
FIGURE 3 | Analysis of seizure latency and length of PTZ-induced
generalized seizures in Epm2a−/− and Epm2b−/− mice. Mice within
2 different age spans (4–8 and 9–23 months) were injected with a
convulsive dose of PTZ (50mg/kg). (A) The time interval between drug
administration and development of generalized tonic-clonic seizures and
(B) the seizure length were measured. Data are presented as mean ±
s.e.m. Student’s t-test was performed for statistical evaluation.
∗p < 0.05 (n = 12–25).
VIDEO-EEG RECORDINGS OF PTZ-INDUCED SEIZURES IN CONTROL,
Epm2a−/−, AND Epm2b−/− MICE AT 16 MONTHS OF AGE
Injections of PTZ at convulsive doses in control mice produced
periods of immobility followed by twitching and hyperextension
of the limbs, further progressing to generalized tonic-clonic
seizures. Intracranial EEG recordings of control, Epm2a−/−, and
Epm2b−/− mice showed different specific patterns of discharges
after 50-mg/kg PTZ injections. Thus, operated control mice
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FIGURE 4 | Intracranial representative recording of control, Epm2a−/−,
and Epm2b−/− mice at 16 months of age after injection of 50mg/kg
pentylenetetrazol (PTZ). (A) Electroencephalographic activity of a control
mouse (A), of an Epm2a−/− mouse (B), and of an Epm2b−/− mouse (C). The
figure shows the records from monopolar electrodes placed over the left
frontal cortex with the reference electrodes implanted posterior to lambda.
(representative example is shown in Figure 4A) showed a pat-
tern of discharges starting 1min and 19 s after PTZ injection, with
isolated spike and spike-wave discharges alternating with immo-
bility periods during 3min. At this point, rhythmic isolated spike
and spike-wave discharges with muscular jerk correlates were
shown over a period of 5min; these evolved to generalized tonic-
clonic seizures with low-frequency (3–6Hz) spike-wave correlates
lasting 22 s. The tonic-clonic seizure began with a tonic phase
that was followed by a clonic stage and an after-seizure period
of immobility. A representative EEG recording of an Epm2a−/−
mouse after PTZ injection (Figure 4B) displayed a significantly
shorter period of time (1min and 30 s) before a brief 1-min
initial stage of irregular twitches and myoclonus that correlated
with spike and spike-wave complexes and that evolved into a
tonic-clonic seizure lasting 29 s. This seizure started with a tonic
phase lasting 14 s with hyperextension of the limbs and was fol-
lowed by a 4-s period of clonic stage and a 24-s period of tonic
hind-limb extension. The first 11 s of this tonic phase presented
with spike-wave complex correlates and concluded with a 13-s
period of non-neuronal activity. A representative example of EEG
recording of an Epm2b−/− mice (Figure 4C) showed a 1-min
period of normal activity after PTZ injection, which was followed
by myoclonus, muscular jerks, and twitches with EEG corre-
lates of spikes and spike-wave and polyspike-wave complexes over
a period of 3min, preceding a generalized tonic-clonic seizure
lasting 22 s. This seizure started with a 3-s tonic phase with hyper-
extension of the limbs that was followed by a prominent tonic-
clonic stage lasting 19 s. The post-seizure period of non-neuronal
activity was almost absent in the Epm2b−/− model while post-
ictal discharges with myoclonic correlates started suddenly in
this model.
DISCUSSION
Although a great effort has been devoted to understanding the
basis of the formation of Lafora bodies and their relationship to
autophagy and alterations in glycogen metabolism (Gentry et al.,
2007; Tagliabracci et al., 2008; Aguado et al., 2010; Criado et al.,
2012), the relationships between the development of Lafora bod-
ies and the induction of abnormal electroencephalographic activ-
ity remain unknown. Lafora disease patients present a distinctive
EEG pattern characterized by slowing of background activity with
recurrent epileptiform discharges: 3–6Hz spikes/polyspikes, with
or without slow waves (Van Heycop Ten Ham, 1974), similar to
that observed in spontaneous seizures developed by Epm2a−/−
and Epm2b−/− mice (Ganesh et al., 2002; Garcia-Cabrero et al.,
2012).
It has been previously reported that the lack of expression
of malin protein in a different Epm2b−/− mice model (Valles-
Ortega et al., 2011) resulted in an increase in the susceptibil-
ity to pharmacologically induced hippocampal seizures using
the epileptogenic kainic acid. PTZ is a widely used chemi-
cal for the induction of generalized epilepsy. It has also been
extensively used to test antiepileptic drugs on laboratory ani-
mals (Stone, 1970). Although animal models based on PTZ are
widely used, the mechanism by which PTZ elicits its action is
not very well understood. At the molecular level, a generally
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accepted mechanism of PTZ is non-competitive antagonism
of the gamma-aminobutyric acid GABAA receptor complex.
Additionally, alterations in voltage-dependent calcium and potas-
sium channels and changes in the serotonergic and in the
NMDA receptor-mediated glutamate neurotransmission are also
generated after PTZ treatment. Treatment with PTZ in mice
induces a wide range of responses, from mild convulsions to
generalized seizures, all of them as a result of an excess of
activation of neurons located in the frontal cortex, the amyg-
dala, the cerebellum, the brainstem, and other regions of the
brain.
In this study we have undertaken a systematic evaluation of
PTZ-induced seizure responses in Epm2a−/− and Epm2b−/−
mice. Both models present a significantly increased sensitivity to
PTZ that is more noticeable in the presence of myoclonus at sub-
convulsive doses. Although both Epm2a−/− and Epm2b−/− mice
trend to present more myoclonic jerks with age, no statistical dif-
ferences were found between young and older mice. At convulsive
doses, the percentage of Epm2a−/− and Epm2b−/− mice show-
ing generalized seizures was significantly increased, as was seizure
length, while the latency time to the appearance of these seizures
experienced a statistically significant reduction when compared
to age-matched controls. Although old Epm2b−/− mice trended
to be more resistance to PTZ than young animals, no signifi-
cant differences were found between all aged groups. It has been
widely reported that number of Lafora bodies increases with age
in brain of Epm2a−/− and Epm2b−/− mice (Ganesh et al., 2002;
Criado et al., 2012; Garcia-Cabrero et al., 2012). Moreover, alter-
ations in motor coordination, activity impairment and memory
deficits progressively increase with age in both Epm2a−/− and
Epm2b−/− mice (Garcia-Cabrero et al., 2012), probably reflect-
ing the increased accumulation of Lafora bodies in multiple brain
regions. However, myoclonus and seizures were observed in both
mutant mouse strains regardless of age. Thus, it seems likely that
development of Lafora bodies does not interfere with the induc-
tion of abnormal electroencephalographic activity in our mouse
models.
The lack of laforin and malin expression may induce some
aberrant activity of neuronal networks, resulting in increased
GABAA receptor-mediated hyperexcitability. EEG records of
PTZ-induced seizures in Epm2a−/− and Epm2b−/− mice showed
the presence of characteristic patterns of discharges. Both
Epm2a−/− and Epm2b−/− mice display a shorter period of
latency with irregular spike and spike-wave discharges before
the appearance of the tonic-clonic seizure as compared to age-
matched controls. Moreover, post-ictal discharges withmyoclonic
correlates started suddenly in both models. This behavior may
reflect the existence of alterations in the GABAergic neurotrans-
mission which could be involved in the generation of epileptic
traits.
Overall, our results show that mice lacking expression of either
laforin or malin display different degrees of increased GABAA
receptor-mediated hyperexcitability after administration of the
epiletogenic agent PTZ. Our Epm2a−/− and Epm2b−/− models
may assist in understanding the way laforin and malin mutations
regulate excitotoxic damage and in assaying novel agents aimed at
reducing epileptic seizures in this devastating disease.
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